Please login to the form below

Not currently logged in
Email:
Password:

Elocta

This page shows the latest Elocta news and features for those working in and with pharma, biotech and healthcare.

Sobi takes ownership of rare disease drug Gamifant for $518m

Sobi takes ownership of rare disease drug Gamifant for $518m

Sobi’s president and chief executive Guido Oelkers had promised new acquisitions to bolster the firm’s growth, which is being led by its haemophilia treatments, Elocta and Alprolix..

Latest news

  • Sobi shows strong growth despite haemophilia competition Sobi shows strong growth despite haemophilia competition

    The company markets Elocta, a recombinant clotting factor VIII therapy for haemophilia A that offers an extended half-life, and Alprolix, a long-lasting recombinant factor IX Fc fusion protein for ... Standard factor VIII therapy requires administration

  • Shire claims EU approval for haemophilia A drug Adynovi Shire claims EU approval for haemophilia A drug Adynovi

    The drug will battle Bayer’s Kovaltry and Sobi's Elocta in a bid to capture market share. ... It is jostling for market share with other long-acting Factor VIII products for haemophilia A, including Bayer’s Kovaltry and Sobi's Elocta and while Shire

  • Sobi looks to real-world trial to push Elocta take-up Sobi looks to real-world trial to push Elocta take-up

    Sobi (Swedish Orphan Biovitrum) secured approval for Elocta in Europe at the end of 2015 and started rolling it out in EU markets early last year. ... dose, he noted, adding "A-SURE is an important study that aims to evaluate the effectiveness of Elocta

  • Biogen plans spin-out of haemophilia business Biogen plans spin-out of haemophilia business

    The new publicly-traded company has yet to be named but will start operations with two marketed products - Elocta/Eloctate (efmoroctocog alfa) for haemophilia A and Aprolix (eftrenonacog alfa) for haemophilia

  • Biogen and Sobi's Elocta wins EU approval Biogen and Sobi's Elocta wins EU approval

    Elocta (rFVIIIFc) is indicated for both on-demand prophylaxis treatment of people with haemophilia A of all ages. ... Elocta is the first recombinant clotting factor VIII therapy that offers an extended half-life in the body.

More from news
Approximately 3 fully matching, plus 6 partially matching documents found.

Latest Intelligence

  • A rare opportunity A rare opportunity

    The process is never guaranteed, but we are hoping Elocta will be accessible to patients from 1 July,” he says. ... Compared to normal timelines, the requirements for haemophilia could be quite frustrating, but Neil is sanguine about the need to wait,

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
GCI Health

GCI Health is an integrated communications agency designed for and inspired by the ever-changing face of healthcare. In London, we...

Latest intelligence

Report: Customer experience, shaping digital healthcare
In this issue of ‘Perspective’ we speak with industry experts to learn about the world of digital healthcare, and how pharma is beginning to utilise these modern technologies to enhance...
Biomarker
Encouraging signs in biomarker R&D
The cancer immunotherapy firms ramping-up biomarker R&D...
Programmatic methodology and why you should be using it
What is it? How does it work? Why is everyone talking about it? By Richard Webb - Associate Director...

Infographics